The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis |
| |
Authors: | Rong Qiu Jingwei Li Yuxuan Xiao Ziyi Gao Yihang Weng Qiran Zhang Chengdi Wang Hanlin Gong Weimin Li |
| |
Affiliation: | aDepartment of Respiratory and Critical Care Medicine;bWest China Medical School/West China Hospital;cWest China School/Hospital of Stomatology;dDepartment of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China. |
| |
Abstract: | Background:Coronavirus disease 2019 (COVID-19) has spread almost all regions of the world and caused great loss to the whole body of mankind. Thus, numerous clinical trials were conducted to find specific medicine for COVID-19 recently. However, it remains unanswered whether they are beneficial.Objective:This study aimed to evaluate the efficiency and safety of the COVID-19 medicine.Methods:Studies were determined through searching PubMed, Embase, Cochrane Library, and Medline. The studies of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement, and rate of serious adverse events.Results:A total of 33 studies involving 37,879 patients were included in our study, whose intervening measures contained three major types of COVID-19 medicine, ACEI/ARB, antiviral medicine, and chloroquine/hydroxychloroquine. Compared to control group, COVID-19 drugs have no distinct effect on mortality (RR, 0.93; 95% CI, 0.79–1.11, P = .43) and discharge rate (RR, 1.06; 95% CI, 0.98–1.14, P = .13). However, antiviral medicine presents the obvious advantage in clinical improvement (RR, 1.11; 95% CI, 1.01–1.23, P < .05). In addition, the serious adverse events rate (RR, 0.75; 95% CI, 0.63–0.88, P < .05) of COVID-19 medicine is lower than control group.Conclusion:The results indicated antiviral medicine was potential specific medicine for COVID-19 treatment by improving clinical symptoms, but it failed to increase the discharge rate and reduce mortality. Chloroquine/hydroxychloroquine and ACEI/ARB had no significant effect on treatment of COVID-19, thus they were not recommended for routine medication. Moreover, more trials are needed to find effective drugs to lower the mortality of COVID-19 patients. |
| |
Keywords: | COVID-19 efficiency drugs meta-analysis safety |
|
|